U.S., Dec. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07291102) titled 'Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma' on Nov. 21.
Brief Summary: This is a trial to compare neurocognitive outcomes in the intent-to-treat population 2.5 years after diagnosis between patients with newly diagnosed, non-metastatic, SHH-activated, TP53-wt, non-MYC amplified MF randomized to the interventional arms A ("Head Start 4") or B (HIT-SKK).
Study Start Date: July 01, 2026
Study Type: INTERVENTIONAL
Condition:
Medulloblastoma
Intervention:
DRUG: Bridging Chemotherapy
One bridging chemotherapy cycle consists of five days of therapy using Carboplatin and eto...